Human Genome Editing Webinar with NAS/NAM

Collaborative approaches can help develop the quality and efficiency of the clinical microbiology laboratory with the goal of improving patient outcomes.

Gene therapy has made tremendous strides over the past decade or so. The first approved drugs are on the market, and literally hundreds of trials are underway offering unprecedented hope to patients with rare, debilitating genetic disorders. Nevertheless, safety issues continue to swirl around the field as adverse events are reported in trials involving both lentivirus and AAV vectors. Pricing and manufacturing pose additional hurdles that could significantly challenge the field.

CMIC Group, the first and largest CRO in Japan with extended services in drug development and GMP manufacturing in the US, Japan and Asia, held a webinar Advanced ODT Technologies for Drug Development in Japan and the US on April 11, 2019.Since its introduction in the 1980s, the market of orally disintegrating tablet (ODT) has grown annually and ODTs are now available in a variety of therapeutic areas, both over-the-counter (OTC) and by prescription. ODT market is projected to reach US$21B in 2023.In this webinar, CMIC and Aprecia experts talked about advanced ODT technologies and its advantages in drug development.

You will be hearing from a variety of Scientists from Wyatt Technology who will help explain some of the key advancements and improvements made in light scattering that we believe will provide future customers with state-of-the-art capabilities and unique benefits.